Anavex Life Sciences Corp. (AVXL)’s Financial Results Comparing With X4 Pharmaceuticals Inc. (NASDAQ:XFOR)

Since Anavex Life Sciences Corp. (NASDAQ:AVXL) and X4 Pharmaceuticals Inc. (NASDAQ:XFOR) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences Corp. 3 0.00 47.30M -0.52 0.00
X4 Pharmaceuticals Inc. 13 0.00 7.31M -20.25 0.00

Table 1 demonstrates Anavex Life Sciences Corp. and X4 Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences Corp. 1,608,679,386.46% -127.1% -102.3%
X4 Pharmaceuticals Inc. 55,547,112.46% -150.3% -87%


The Current Ratio and Quick Ratio of Anavex Life Sciences Corp. are 3.2 and 3.2 respectively. Its competitor X4 Pharmaceuticals Inc.’s Current Ratio is 1.6 and its Quick Ratio is 1.6. Anavex Life Sciences Corp. can pay off short and long-term obligations better than X4 Pharmaceuticals Inc.

Analyst Recommendations

Anavex Life Sciences Corp. and X4 Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Anavex Life Sciences Corp. 0 0 2 3.00
X4 Pharmaceuticals Inc. 0 0 0 0.00

Anavex Life Sciences Corp. has an average target price of $13, and a 326.23% upside potential.

Institutional & Insider Ownership

Institutional investors held 14.2% of Anavex Life Sciences Corp. shares and 47.8% of X4 Pharmaceuticals Inc. shares. 5.43% are Anavex Life Sciences Corp.’s share held by insiders. Competitively, insiders own roughly 2% of X4 Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anavex Life Sciences Corp. -3.03% -33.33% -16.34% 37.63% -11.11% 64.1%
X4 Pharmaceuticals Inc. -4.88% -24.44% -42.79% -29.17% -18.72% -14.51%

For the past year Anavex Life Sciences Corp. had bullish trend while X4 Pharmaceuticals Inc. had bearish trend.


Anavex Life Sciences Corp. beats on 8 of the 10 factors X4 Pharmaceuticals Inc.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.